Somatostatin receptor PET (68Ga/64Cu-DOTATATE)
A PET scan using a radioactive hormone mimic that lights up neuroendocrine tumours and shows whether the matching radioactive treatment will work.
Overview
68Ga-DOTATATE (Netspot, 2016), 68Ga-DOTATOC (2019) and 64Cu-DOTATATE (Detectnet, 2020) replaced 111In-octreotide scintigraphy, with far higher sensitivity for small lesions and bone disease. Mandatory for staging, for selecting patients for PRRT (Krenning score ≥3 or uptake above liver), and for detecting occult primaries. FDG PET complements it in high-grade or dedifferentiated disease ('flip-flop' pattern).
How it works
Radiolabelled somatostatin analogue binds SSTR2 on tumour cells; positron emission imaged by PET/CT.
- Whole-body receptor map
- Theranostic gatekeeper for 177Lu-DOTATATE
- Changes management in ~40% of patients versus conventional imaging
- Physiologic uptake in pancreas uncinate, spleen, pituitary
- Poor sensitivity in SSTR-negative high-grade disease
- 68Ga generator supply and short half-life
Dependencies
Open the dependency map →Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
An injectable tracer that sticks to a marker (somatostatin receptor) many neuroendocrine tumours carry. A PET scan afterwards shows where those tumours are, including small deposits that other scans can miss.
The PET scan for neuroendocrine tumours that finds far more disease than older scans and confirms eligibility for lutetium radioligand therapy (the theranostic pair).
A cousin of the Ga-68 DOTATATE and Cu-64 DOTATATE scans: it sticks to the same receptor on neuroendocrine tumours and lets PET find them. It is FDA-approved but, unusually, has no brand name and no pharmaceutical-company sponsor.
Latest papers
topQuery for this technology: (TITLE:"Somatostatin receptor PET" OR ABSTRACT:"Somatostatin receptor PET" OR TITLE:"68Ga/64Cu-DOTATATE" OR ABSTRACT:"68Ga/64Cu-DOTATATE") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Somatostatin receptor PET (68Ga/64Cu-DOTATATE), not a curated reading list.
Similar pages
not linked directly; found by shared links- AgentIndium-111 pentetreotide
Shares Copper-64 dotatate, Gallium-68 edotreotide (DOTATOC), Indium-111, Gallium-68 DOTATATE (and Cu-64 DOTATATE).
- TermPRRT (peptide receptor radionuclide therapy)
Shares Grade 3 well-differentiated neuroendocrine tumour, Gallium-68 DOTATATE (and Cu-64 DOTATATE), Copper-64, Theranostics.
- Agent177Lu-edotreotide
Shares Krenning score, SSTR PET → PRRT, Gallium-68 edotreotide (DOTATOC), Grade 3 well-differentiated neuroendocrine tumour.
- TrialStudy to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Shares Advanced Accelerator Applications (Novartis), Grade 3 well-differentiated neuroendocrine tumour, Lung neuroendocrine tumours (typical and atypical carcinoid), Pancreatic neuroendocrine tumours.
- Key paperNETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours
Shares Grade 3 well-differentiated neuroendocrine tumour, SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha, Theranostics, Pancreatic neuroendocrine tumours.
- AgentFluorodopa F-18
Shares Copper-64 dotatate, Gallium-68 edotreotide (DOTATOC), Metastatic pheochromocytoma and paraganglioma, Pheochromocytoma and paraganglioma (PPGL).
- TrialNETTER-1
Shares Krenning score, SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours.
- TermNeuroendocrine tumour grade (Ki-67) and WHO classification
Shares Grade 3 well-differentiated neuroendocrine tumour, Lung neuroendocrine tumours (typical and atypical carcinoid), Small-cell lung cancer, Pancreatic neuroendocrine tumours.